GT Biopharma Change In Cash Over Time
| GTBP Stock | USD 2.86 0.19 6.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out GT Biopharma Performance and GT Biopharma Correlation. GTBP |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.39) | Return On Assets (0.61) | Return On Equity (1.31) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare GT Biopharma and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (1.8 M) | 1.3 M | (1.2 M) | 19.3 M | (17.5 M) | (1.9 M) | (1.8 M) |
| NRBO | 314 K | 314 K | 314 K | 314 K | 314 K | 3.3 M | 20.4 M | (5.6 M) | 481 K | 11.1 M | (3.8 M) | 6.3 M | 17 M | (10.9 M) | (10.4 M) |
| VRAX | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (40 K) | (5 K) | 4.1 K | 9.3 M | (5.8 M) | (5.5 M) |
| QNRX | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.6 M) | 5.2 M | (4.9 M) | 7.2 M | (4.6 M) | (459.4 K) | (482.4 K) |
| VRPX | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (124.9 K) | (6.8 K) | 13.3 K | 36.8 M | (17.8 M) | (9.9 M) | (9.4 M) |
| REVB | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | (40.6 M) | 65.7 M | 10.7 M | (74.2 M) | (3.2 M) | 4 M | 6.7 M | 12.3 M |
| BDRX | 133 K | 133 K | 133 K | 2.3 M | 27.9 M | (14.2 M) | 1.4 M | (4.4 M) | (10.9 M) | 8.6 M | (3.4 M) | 2.5 M | (7.2 M) | 3.1 M | 3.3 M |
| PRAX | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 26.9 M | 251.8 M | (157.5 M) | (77.7 M) | 19.7 M | 10.7 M |
| PULM | 96 K | 96 K | 96 K | 15.5 M | 15.5 M | 18.5 M | (14.7 M) | (632 K) | (987 K) | 20.9 M | 8.2 M | 23.6 M | (18.2 M) | (16.6 M) | (15.8 M) |
| AKTX | 6 K | (3 K) | 1.1 M | 6.6 M | (1.4 M) | 65.6 M | (34.8 M) | (6 M) | (6 M) | (236 K) | 8.3 M | (4.7 M) | 3.9 M | (9.4 M) | (8.9 M) |
| SONN | 43.6 K | 43.6 K | (781.1 K) | (196.9 K) | (196.9 K) | 1.3 M | 169.9 K | 85.6 K | 85.6 K | 30.2 K | 20.3 M | (24.6 M) | (778.6 K) | 30.2 K | 28.7 K |
| CINGW | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | (644.7 K) | 779.2 K | 15.3 M | (11.1 M) | (5.3 M) | (5 M) |
| SABS | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | 6.3 M | 26.9 M | 26.9 M | 41.5 M | 21 M |
| ANEB | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 17 M | (5.4 M) | (3.3 M) | (8.2 M) | (7.7 M) |
| CVKD | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 32.6 K | 8.4 M | 4.6 M |
| MNPR | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 67.9 K | 6.9 M | (2.9 M) | 6.3 M | 3.5 M | 3.6 M | (12.1 M) | (920.1 K) | (874.1 K) |
| TARA | 66 M | 66 M | 66 M | 66 M | 66 M | (28.8 M) | (3.6 M) | (15.2 M) | (1.8 M) | (13.2 M) | 168.8 M | (132.9 M) | (11.6 M) | 15.5 M | 16.2 M |
| VCNX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | 2.5 M | 1.4 M | (2.8 M) | 7.8 M | (2 M) | (2.2 M) | (4.9 M) | (4.6 M) |
| SRZN | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 5.9 M | (1.9 M) | (8.4 M) | 11.6 M | 5.9 M |
GT Biopharma and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Change In Cash description
My Equities
My Current Equities and Potential Positions
| GT Biopharma | GTBP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.86
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.